Thyroid Cancer Genetics Study Finds New Mutations
By LabMedica International staff writers Posted on 08 May 2018 |

Image: A histopathology micrograph of anaplastic thyroid carcinoma (Photo courtesy of The Clayman Thyroid Cancer Center).
Anaplastic thyroid cancer (ATC) is a form of thyroid cancer, which has a very poor prognosis due to its aggressive behavior and resistance to cancer treatments. Its anaplastic cells have poor differentiation, including dedifferentiation.
A new study has defined the genetic landscape of advanced differentiated and anaplastic thyroid cancer and identified genetic alterations of potential diagnostic, prognostic and therapeutic significance.
Scientists at the University of Colorado Cancer Center (Aurora, CO, USA) and their colleagues recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. Genetic profiles were generated and analyzed with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and FoundationOne (Foundation Medicine, Cambridge, MA, USA).
The investigators found that patients with ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared to other thyroid cancer types. DNA mismatch repair deficit and activity of Apolipoprotein B mRNA Editing Catalytic Polypeptide (APOBEC) cytidine deaminases were identified as mechanisms associated with high mutational burden in a subset of differentiated and anaplastic thyroid cancers. Copy number losses and mutations of CDKN2A and CDKN2B, amplification of CCNE1, amplification of receptor tyrosine kinase genes KDR, KIT and PDGFRA, amplification of immune evasion genes CD274, PDCD1LG2 and JAK2 and activating point mutations in small GTPase RAC1 were associated with ATC.
Nikita Pozdeyev, MD, PhD, an assistant professor and lead author of the study, said, “Genetic analysis of early-stage thyroid cancers is most often not necessary as we successfully treat these tumors with surgery and radioactive iodine. But with distant metastases, genetic information becomes important for treatment. Because oncologists had sought this genetic information, our study is enriched for advanced cases.” The study was published on April 3, 2018, in the journal Clinical Cancer Research.
Related Links:
University of Colorado Cancer Center
Memorial Sloan Kettering Cancer Center
FoundationOne
A new study has defined the genetic landscape of advanced differentiated and anaplastic thyroid cancer and identified genetic alterations of potential diagnostic, prognostic and therapeutic significance.
Scientists at the University of Colorado Cancer Center (Aurora, CO, USA) and their colleagues recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. Genetic profiles were generated and analyzed with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and FoundationOne (Foundation Medicine, Cambridge, MA, USA).
The investigators found that patients with ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared to other thyroid cancer types. DNA mismatch repair deficit and activity of Apolipoprotein B mRNA Editing Catalytic Polypeptide (APOBEC) cytidine deaminases were identified as mechanisms associated with high mutational burden in a subset of differentiated and anaplastic thyroid cancers. Copy number losses and mutations of CDKN2A and CDKN2B, amplification of CCNE1, amplification of receptor tyrosine kinase genes KDR, KIT and PDGFRA, amplification of immune evasion genes CD274, PDCD1LG2 and JAK2 and activating point mutations in small GTPase RAC1 were associated with ATC.
Nikita Pozdeyev, MD, PhD, an assistant professor and lead author of the study, said, “Genetic analysis of early-stage thyroid cancers is most often not necessary as we successfully treat these tumors with surgery and radioactive iodine. But with distant metastases, genetic information becomes important for treatment. Because oncologists had sought this genetic information, our study is enriched for advanced cases.” The study was published on April 3, 2018, in the journal Clinical Cancer Research.
Related Links:
University of Colorado Cancer Center
Memorial Sloan Kettering Cancer Center
FoundationOne
Latest Molecular Diagnostics News
- Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
- First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
- New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
- Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
- First-of-its-Kind Blood Test Detects Trauma-Related Diseases
- Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more